XOMA Royalty Closes Acquisition of LAVA <a href="https://laohu8.com/S/LENZ">Therapeutics</a>
XOMA Royalty Corporation has completed its previously announced acquisition of all outstanding common shares of LAVA Therapeutics N.V. LAVA shareholders received $1.04 in cash per share and a non-transferable contingent value right $(CVR)$, which entitles holders to certain future cash payments. These payments include the right to receive 75% of any net proceeds related to LAVA's two partnered assets and from any out-license or sale of unpartnered programs, as well as up to approximately $0.23 per CVR, depending on the final determination of certain potential liabilities. Following the completion of the transaction, XOMA Royalty now owns 100% of LAVA's successor, and public trading of LAVA shares has been suspended with plans to delist from Nasdaq.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580165-en) on November 21, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。